Compare PBF & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | CPRX |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.0B |
| IPO Year | 2011 | 2006 |
| Metric | PBF | CPRX |
|---|---|---|
| Price | $42.68 | $23.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $31.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.1M |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ 69.78 | 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | ★ $24,508,200,000.00 | $119,072,803.00 |
| Revenue This Year | $1.73 | $8.00 |
| Revenue Next Year | $0.67 | $9.77 |
| P/E Ratio | ★ N/A | $14.53 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $13.62 | $19.05 |
| 52 Week High | $47.18 | $26.56 |
| Indicator | PBF | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 43.93 |
| Support Level | $27.35 | $22.46 |
| Resistance Level | $47.18 | $24.86 |
| Average True Range (ATR) | 2.88 | 0.99 |
| MACD | 0.30 | -0.05 |
| Stochastic Oscillator | 68.76 | 38.29 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.